Ultime notizie per GSK (NYSE:GSK) Azioni

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GlaxoSmithKline

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Scopri i migliori titoli a dividendo del settore sanitario: analisi delle opportunità di investimento in Pfizer, GSK e CVS.

Titoli a dividendo: le migliori opportunità del settore sanitario

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK PLC

Goldseek Resources Inc Ordinary Shares

A child in Alameda County, California is the latest case of <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">bird flu in the U.S.</a> 
According to the <a href="https://www.latimes.com/environment/story/2024-11-19/alameda-county-child-believed-to-be-latest-case-of-bird-flu-source-unknown">Los Angeles Times</a>, the total case count in the U.S. stands at 54. Thirty-one cases are attributed to the dairy industry and 21 to the poultry industry. Two of the case&#8217;s causes are unknown.
Companies are <a href="https://www.benzinga.com/general/biotech/23/03/31416800/large-vaccine-players-including-gsk-moderna-prepare-for-bird-flu-vaccine-just-in-case">racing to develop vaccines</a>, but observers worry that the incoming Trump administration&#8217;s selection of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services could put a potential treatment in the crosshairs.
Health researchers are exploring the idea that the virus was spread via wild birds. The California child&#8217;s genetic sequencing has not been released; it is therefore unclear if it is of wild bird or dairy origins.
Meanwhile, a teenager in Canada who was hospitalized with the bird flu possibly showed signs of mutation, the Guardian <a href="https://www.theguardian.com/world/2024/nov/19/bird-flu-cases-mutation-canada">reports</a>.
Experts are reportedly concerned that a mutation in the virus would make it easier to spread, making the odds of a widespread outbreak more likely.
Vaccine Efforts: Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) are currently developing an <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">mRNA bird flu vaccine</a> using similar technology to the companies' COVID-19 vaccines.
The U.S. government has <a href="https://www.benzinga.com/general/biotech/24/10/41188886/gsk-sanofi-and-csl-secure-us-government-fund-to-boost-bird-flu-vaccine-production-report">also awarded grants</a> to European pharmaceutical giants GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Regulatory Question Marks: Kennedy, Donald Trump&#8217;s pick to lead the HHS, is widely known as <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">a vaccine-skeptic</a>. While the Kennedy family heir says he will not &#8220;take away anybody's vaccines,&#8221; his ultimate regulatory intentions are unclear. A bird flu vaccine could face additional hurdles in a Trump administration.
In the past, Kennedy has falsely associated <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">vaccinations with autism</a> in children, a claim that has been thoroughly disproven in the scientific field. A May Lancet <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">study</a> found that vaccines have saved 154 million lives throughout human history. They have effectively treated polio, measles, pertussis, and other diseases.
Kennedy may face a tough confirmation vote in the Republican-controlled Senate given his pro-choice abortion stances. He has, however, found a unique <a href="https://x.com/jaredpolis/status/1857173250586911189">ally</a> in Colorado Governor Jared Polis, a Democrat.
Pfizer, Moderna and other vaccine manufacturers&#8217; stock fell on the news of Kennedy&#8217;s selection.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/events/24/11/42073346/exclusive-retail-investors-are-taking-on-more-risk-and-finding-success-is-crypto-acting-as-a-gateway-trade">EXCLUSIVE: Retail Investors Are Taking On More Risk And Finding Success — Is Crypto Acting As A &#8216;Gateway Trade?&#8217;</a></li>
</ul>
Image: Shutterstock

Equities

Health Care

MRNA

Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?

On Tuesday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease.
GLISTEN <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/" rel="noreferrer noopener">met</a> its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market &#8211; Here&#8217;s Why</a>
The trial recruited PBC patients with moderate to severe itch who were receiving stable doses of guideline-suggested therapies for pruritus, were treatment naïve, or had been previously treated.
The preliminary safety results are generally consistent with those seen in prior studies of linerixibat. Further analysis of these data is ongoing.
Kaivan Khavandi, SVP &amp; Global Head, Respiratory/Immunology R&amp;D,&nbsp;GSK, said: &#8220;Linerixibat has the potential to be the first global therapy specifically developed to treat itch in PBC.&#8221;
People who have been diagnosed with PBC will reach 510,000 globally by 2030, and more than 240,000 people will experience relentless itch requiring treatment.
The full results of GLISTEN will be presented at a future scientific congress.
Investigational Linerixibat has been granted Orphan Drug Designation in the U.S. and EU.
In August this year, GSK <a target="_blank" href="https://www.nice.org.uk/guidance/awaiting-development/gid-ta11307" rel="noreferrer noopener">requested</a> a timeline adjustment, so the appraisal is expected to start in late September 2025. Submissions will be due around late November 2025.
This change allows the company more time to prepare a thorough and detailed submission for the National Institute for Health and Care Excellence (NICE).
Price Action: GSK stock is down 0.56% at $33.50 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42061321/vipshop-q3-earnings-revenue-beats-estimates-despite-order-decline-strong-margins-amid-soft-sales-reveals-q4-guidance-and-share-buybacks" target="_blank" rel="noreferrer noopener">Vipshop Beats Q3 Estimates Despite Sales Dip, Focuses On Long-Term Resilience</a></li>
</ul>

Biotech

Large Cap

General

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

GSK Announces Its GLISTEN Study Met Its Primary Endpoint, With Linerixibat Resulting In An Improvement In Itch

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html" title="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html</a>

NVAX

U.S. CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Eurozone

Movers

BNTX

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

On Thursday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35954764/gsk-frames-a-comeback-for-its-multiple-myeloma-drug-following-encouraging-phase-3-data" rel="noreferrer noopener">refractory multiple myeloma</a>.
The trial <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsedrefractory-multiple-myeloma/" rel="noreferrer noopener">met</a> the key secondary endpoint of overall survival (OS), showing that belantamab mafodotin when combined with BorDex significantly reduced the risk of death versus standard of care daratumumab plus BorDex.
The interim analysis results, including safety data, will be presented at the upcoming American Society of Hematology Annual Meeting and Exposition.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">GSK&#8217;s Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024</a>
A phase 3 study in newly diagnosed transplant-ineligible multiple myeloma is expected to be initiated by the end of 2024 as part of the DREAMM program.
In 2024, belantamab mafodotin combinations have been filed in the U.S.,&nbsp;European Union,&nbsp;Japan, United Kingdom, Canada, and Switzerland for relapsed or refractory multiple myeloma based on the results of the DREAMM-7 and DREAMM-8 trials.
In 2022, GSK withdrew the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial,&nbsp;which did not meet the requirements of the FDA <a target="_blank" href="https://www.benzinga.com/general/biotech/22/11/29818040/after-disappointing-confirmatory-study-gsk-to-withdraw-approved-blood-cancer-drug-in-us" rel="noreferrer noopener">Accelerated Approval regulations</a>.&nbsp;
In June, GSK released&nbsp;results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39144773/gsks-blenrep-combo-therapy-cuts-risk-of-disease-progression-or-death-by-around-50-in-pretreated-m" rel="noreferrer noopener">refractory multiple myeloma</a>.
On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin combination (n=155) showed a statistically significant and clinically meaningful improvement compared to the bortezomib combination (n=147).
Price Action: GSK stock is down 0.01% at $35.11 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41977487/ac-immunes-active-immunotherapy-shows-antibody-responses-in-early-parkinsons-patients" target="_blank" rel="noreferrer noopener">AC Immune&#8217;s Active Immunotherapy Shows Antibody Responses In Early Parkinson&#8217;s Patients</a></li>
</ul>

GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease" rel="noreferrer noopener">seven years ago</a>.
This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive lung condition that impedes breathing due to obstructed airflow.
COPD often manifests as chronic bronchitis and emphysema, typically developing from prolonged exposure to irritants like cigarette smoke, air pollution, or occupational dust.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39312759/regenerons-dupixent-copd-sales-to-reach-20b-by-2026-analyst-sees-larger-addressable-market" rel="noreferrer noopener">Regeneron&#8217;s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market</a>
The condition impacts millions globally, with a 2023 analysis by DelveInsight <a target="_blank" href="https://www.prnewswire.com/news-releases/sanofiregeneron-pharmaceuticals-dupixent-approval-marks-a-significant-shift-in-chronic-obstructive-pulmonary-disease-treatment-landscape--delveinsight-302302232.html" rel="noreferrer noopener">reporting</a> around 44 million diagnosed cases across seven major markets, with projections of continued growth at a 1.4% CAGR through 2034.
COPD management typically involves medications like bronchodilators, which ease breathing by relaxing airway muscles.
These drugs, often used in inhalers, can include steroids to reduce inflammation in severe cases. Common options include short—and long-acting bronchodilators like Albuterol, Ipratropium, and Aclidinium. LABAs and LAMAs are also prevalent, with combinations such as LABA+ICS (e.g., AstraZeneca Plc&#8217;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) Symbicort, GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Advair) and LABA+LAMA (e.g., GSK&#8217;s Anoro Ellipta, Boehringer Ingelheim&#8217;s Stiolto Respimat) available for comprehensive treatment.
The introduction of Dupixent changes the treatment landscape by specifically targeting type 2 inflammation pathways (IL-4 and IL-13), which play a role in COPD patients with elevated eosinophils prone to frequent exacerbations.
The Phase 3 BOREAS trial demonstrated that DUPIXENT reduced moderate-to-severe exacerbations by 30% over 52 weeks and improved lung function, with prebronchodilator FEV1 increasing by 160 mL compared to 77 mL in the placebo group.
The drug also had a favorable safety profile, indicating its potential as a game-changer for those with type 2 inflammation.
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron&#8217;s itepekimab, AstraZeneca&#8217;s benralizumab, Amgen Inc NASDAQ: AMGN/AstraZeneca&#8217;s tezepelumab, and GSK&#8217;s mepolizumab are in development, promising more options to transform COPD management.
On Wednesday, Regeneron announced that new and updated data from its hematology pipeline will be presented in 23 abstracts at the American Society of Hematology <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41934824/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-o" rel="noreferrer noopener">2024 Annual Meeting</a>.
Price Action: REGN stock traded lower by 0.98% to $812.92 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41939018/japan-increases-semiconductor-funding-as-us-trade-policies-pressure-taiwan-semiconductor" target="_blank" rel="noreferrer noopener">Japan Increases Semiconductor Funding As US Trade Policies Pressure Taiwan Semiconductor</a></li>
</ul>
Photo by Minerva Studio via Shutterstock

REGN

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

On Thursday, genetics-led consumer healthcare company 23andMe Holding Co.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) announced a business restructuring to streamline <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41889319/23andme-announces-business-restructuring-to-streamline-operations-reduce-costs-and-position-compan" rel="noreferrer noopener">operations and reduce costs</a>.
In addition, 23andMe is discontinuing the further development of all its therapeutic programs while evaluating strategic alternatives for its clinical and preclinical assets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41146410/legal-battle-brews-over-23andmes-customer-data-breach-settlement-and-arbitration-claimants" rel="noreferrer noopener">Legal Battle Brews Over 23andMe&#8217;s Customer Data Breach Settlement And Arbitration Claimants</a>
The company is reducing its overall headcount by over 200 employees, representing approximately 40% of the workforce.
The business restructuring is expected to substantially reduce operating expenses and result in annualized cost savings of more than $35 million. The company expects to incur up to $12 million in costs and expenses.
&#8220;We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,&#8221; said Anne Wojcicki, 23andMe&#8217;s CEO, Co-Founder, and Chair of the Board.
The company is actively exploring all strategic options in parallel with discontinuing its therapeutics division.
23andMe intends to wind down its ongoing clinical trials as quickly as practical while the strategic alternatives process continues.
The company&#8217;s therapeutic programs include 23ME-00610 (a Phase 1/2a therapeutic antibody that is designed to restore the immune system&#8217;s ability to kill cancer cells by blocking the immune checkpoint CD200R1), 23ME-01473 (a Phase 1 therapeutic antibody that targets ULBP6, which can be expressed and secreted by tumor cells to suppress immune activity), and other preclinical immunology and inflammation programs.
In September, independent directors of the Board of&nbsp;23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, providing their resignation,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40918218/independent-board-members-of-penny-stock-23andme-resign-call-out-ceo-anne-wojcicki-for-not-action" rel="noreferrer noopener">effective immediately</a>.
Also, 23andMe reported second-quarter 2025 sales of $44.1 million, down from $50 million a year ago, missing the consensus of $54.3 million.
The decrease was primarily driven by lower consumer services revenue, mainly due to lower PGS kit sales volume and telehealth orders, as well as lower research services revenue as the GSK Plc collaboration exclusive discovery term concluded in July 2023.
Adjusted EBITDA was a loss of $33 million compared to a loss of $45 million a year ago. The company reported a loss per share of $2.32 <a href="https://www.benzinga.com//node/41897482">compared to a $3.17 loss a year ago.</a>
Price Action: ME stock traded higher by 0.43% at $4.63 at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41896233/asia-and-europe-markes-slip-crude-oil-and-dollar-strengthen-on-trumps-tariffs-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia And Europe Markets Cool Off, Dollar Strengthens To 4-month High &#8211; Global Markets Today While US Slept</a></li>
</ul>

Earnings

Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs

Jefferies analyst Peter Welford downgrades GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) from Buy to Hold.

Downgrades

Jefferies Downgrades GSK to Hold

ViiV Healthcare's DOLCE Study Shows 2-Drug Regimen Dovato Is Highly Effective In Treatment-Naïve People With Advanced HIV, Matching 3-Drug Therapy Efficacy At 48 Weeks

President-elect Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. Trading in pharmaceutical stocks is shaky this week and the details are few surrounding a <a href="https://www.benzinga.com/general/politics">possible appointment</a>.
What To Know: Trump <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">recently said</a> he would let Kennedy &#8220;go wild on health&#8221; and could "do pretty much what he wants" in his administration, but the details remain murky.&nbsp;
Kennedy has a record of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies, <a href="https://www.nytimes.com/2024/11/06/us/politics/robert-kennedy-jr-donald-trump-health-care.html">according</a> to The New York Times. Thirteen measles outbreaks have occurred in the U.S. so far in 2024 versus four last year, and the trend coincides with lower measles vaccination rates, The Times report said, citing the CDC. Kennedy is outspoken about certain food ingredients and the state of key public health agencies including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Kennedy said in <a href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">an interview </a>Wednesday with NBC News that Trump has not yet decided what his job in the new administration will be, but he did mention the prospect of being a &#8220;White House health czar.&#8221;
Kennedy said he wouldn&#8217;t "take away anybody&#8217;s vaccines," but the uncertainty surrounding his potential impact on the country's health care regulators caused vaccine-related stocks to drop. Investors may be trying to get ahead of any negative consequences related to a potential Kennedy appointment.  
&#8220;We view the Trump win as mixed for large-cap biopharma since it creates potential uncertainty regarding Food and Drug Administration independence,&#8221; said Leerink Partners analyst David Risinger, according to Investor's Business Daily.  
Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) ending the day down 2.78%, Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 3.9%, BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) down 3.9% and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) closing down by 3.03%. 
Moderna reported its <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">third-quarter results</a> Thursday morning with $1.8 billion in Spikevax sales and was trading down in the late afternoon. Shares of the other vaccine makers are recovering Thursday, but the uncertainty <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">may continue</a> as details emerge on a Kennedy role in the forthcoming Trump administration. 
"Shoot first reaction being felt across the vaccine complex," wrote Mizuho analyst Jared Holz, as <a href="https://www.wsj.com/livecoverage/stock-market-today-fed-meeting-dow-nasdaq-sp500-live-11-06-2024/card/vaccine-stocks-drop-on-worries-about-an-rfk-jr-role-dBPxZf8JJnNqL1Zi5yZY">reported </a>by the Wall Street Journal. He added that "for now, state mandates for many treatments remain intact."
MRNA, PFE, BNTX, GSK Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Moderna shares are up 2.67% at $50.42, Pfizer shares are up 0.35% at $27.44, BioNTech shares are up 1.29% at $108.02 and GSK shares are up 1.77% at $36.54 ahead of the close Thursday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Image: Shutterstock

Government

Politics

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'

<ul>
<li>New analyses highlight use of long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine LA) in clinical trial and real-world populations, and the economic and public health impact of Apretude (cabotegravir LA for PrEP)</li>
<li>Findings from the DOLCE study explore the efficacy of 2-drug regimen Dovato (dolutegravir/lamivudine) compared to three-drug regimen in people with advanced HIV with CD4 count ≤ 200 cells/mm³</li>
<li>Additional key abstracts include findings from pipeline bNAb asset, VH3810109, as a potential approach to treating HIV</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024. Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic.

GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow

GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49

Guggenheim analyst Seamus Fernandez downgrades GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) from Buy to Neutral.

Guggenheim Downgrades GSK to Neutral

<a href="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon" title="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon">https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon</a>

USDA Says H5N1 Bird Flu Detected In Swine For The First Time In U.S. In Oregon Backyard Farm; There Is No Concern About Safety Of The Nation's Pork Supply As A Result Of This Finding On HPAI Detections In Oregon Backyard Farm

USDA To Begin Bulk Milk Testing For Bird Flu Nationwide Following Pressure From Industry And Veterinary Groups; New Effort Aims To Curb Rapid Spread Among Dairy Herds

Wednesday,&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimated sales of $10.78 billion</a>.
Vaccine sales fell 18% (-15% at constant currency) to 2.65 billion pounds.
Vaccine sales performance was primarily impacted by lower sales of Arexvy with changes in Advisory Committee on Immunization Practices (ACIP) guidelines, prioritization of COVID-19 vaccinations in the quarter, lower seasonal infections, and a tough comparator following launch stocking last year.
Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41529605/just-after-pfizers-rsv-vaccine-approval-for-younger-adults-gsk-layouts-encouraging-preliminary-da" rel="noreferrer noopener">Just After Pfizer&#8217;s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population</a>
Specialty Medicine sales increased 14% to 2.97 billion pounds. HIV drug revenues increased by 8% to&nbsp;1.75 billion pounds.
General Medicines sales rose by 3% to&nbsp;2.39 billion pounds. The company added General Medicines, including Trelegy, also continued to perform better than expected.
Trelegy (asthma drug) sales reached 600 million pounds, up 12%
The company reported core EPS of $1.29 (49.7 pence), up 5%&nbsp;on a&nbsp;constant currency and down 1% on a reported basis, beating the consensus of $1.23.
&#8220;Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, &#8221; said Emma Walmsley, CEO.
Guidance:&nbsp;GSK reaffirms 2024 adjusted EPS growth of 10%- 12%, with core operating profit increasing by 11%- 13% and sales expanding by 7% %- 9%.
Vaccine sales are expected to decrease in low-single-digit percent <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40073220/british-pharma-giant-gsks-blockbuster-shingles-and-respiratory-syncytial-virus-vaccine-q2-sales-m" rel="noreferrer noopener">compared to earlier guidance</a> of an increase in low to mid-single-digit percent.
Specialty Medicine revenue is expected to grow at a high teens percent, compared to a prior growth range of mid-to-high teens percent.
General Medicines 2024 sales are forecasted to increase at mid-single digit percent compared to earlier guidance of low to mid-single digit percent.
Price Action:&nbsp;At last check on Wednesday, GSK stock was down 4.69% to $36.38 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41608586/coya-therapeutics-high-dose-interleukin-2-misses-the-mark-in-mid-stage-alzheimers-study" target="_blank" rel="noreferrer noopener">Coya Therapeutics&#8217; High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer&#8217;s Study</a></li>
</ul>
Photo via Wikimedia Commons

Guidance

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024

WIIM

GSK shares are trading lower after the company reported mixed Q3 financial results.

Guidance and outlooks, assumptions and cautionary statements 2024 Guidance&nbsp;
GSK confirms its full-year sales, core profit and EPS guidance at constant exchange rates (CER) and expects to deliver broadly around the middle of the existing ranges.&nbsp;
Turnover is expected to increase between 7 to 9 per cent. Core operating profit is expected to increase between 11 to 13 per cent and Core Earnings per share is expected to increase between 10 to 12 per cent.&nbsp;
The Group revises turnover expectations for Vaccines to a decrease of low-single digit per cent, for Specialty Medicines to an increase of high teens per cent and for General Medicines to an increase of mid-single digit per cent.&nbsp;
This guidance is provided at CER and excludes any contribution from COVID-19 related solutions

GSK Reaffirms Its 2024 Outlook, Sees Turnover Growth Of 7%-9%, With Core Operating Profit Growth Of 11%-13%, And Core EPS Growth Of 10%-12%

GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.23 by 4.88 percent. This is a 1.57 percent increase over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $10.418 billion which missed the analyst consensus estimate of $10.781 billion by 3.37 percent. This is a 1.49 percent increase over sales of $10.265 billion the same period last year.

Earnings Beats

Earnings Misses

GSK Q3 2024 Adj. EPS $1.29 Beats $1.23 Estimate, Sales $10.418B Miss $10.781B Estimate

Medicus Pharma appoints Faisal Mehmud as CMO

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

GSK reports positive Phase 3 results for linerixibat in PBC itching

Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

CDC warns against a spike in COVID, flu cases

CDC warns of an imminent spike in COVID, flu cases

Science 37 (SNCE) was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company...

Science 37 nearly doubles U.S. enrollment for GSK Phase 3 rare disease trial

Optimism over global healthcare sector rises: Jefferies

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

GSK (GSK) announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Ar...

GSK announces Japan's MHLW approved application to extend indication of Arexvy

ABBV

AMGN

ARGX

AZNCF

BGNE

BIIB

BMYMP

BRDCY

CMXHF

CSLLY

ESAIY

ESALF

FUJHY

GILD

GLAXF

KWEB

LEGN

LNVGY

MCHI

MDCX

NONOF

NVSEF

SNYNF

SPGI

SVNDY

UPRO

Press Releases

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Management

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

AGEN

ALEC

ANVS

MYGN

PSNL

QGEN

TSXV:MDCX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

GSK

Notizie

Ultime notizie per GSK (NYSE:GSK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO